CC BY-NC-ND 4.0 · Endosc Int Open 2022; 10(09): E1208-E1217
DOI: 10.1055/a-1859-8277
Original article

Adenoma detection rate is enough to assess endoscopist performance: a population-based observational study of FIT-positive colonoscopies

Bernard Denis
1   Department of Gastroenterology, Pasteur Hospital, Colmar, France
2   ADECA Alsace, Colmar, France
,
Isabelle Gendre
2   ADECA Alsace, Colmar, France
3   CRCDC Grand Est, Colmar, France
,
Nicolas Tuzin
4   Department of Public Health, University Hospital of Strasbourg, Strasbourg, France
,
Juliette Murris
5   Inserm, Centre de recherche des Cordeliers, Université de Paris, Sorbonne Université, Paris, France
6   HeKA, Inria, Paris, France
,
Anne Guignard
1   Department of Gastroenterology, Pasteur Hospital, Colmar, France
,
Philippe Perrin
2   ADECA Alsace, Colmar, France
3   CRCDC Grand Est, Colmar, France
,
Gabriel Rahmi
7   Paris University, PARCC, INSERM, Paris, France
8   Department of Gastroenterology, Georges Pompidou European Hospital, Paris University, Paris, France
› Author Affiliations

Abstract

Background and study aims Neoplasia-related indicators, such as adenoma detection rate (ADR), are a priority in the quality improvement process for colonoscopy. Our aim was to assess and compare different detection and characterization indicators in fecal immunochemical test (FIT)-positive colonoscopies, to determine associated factors, and to propose benchmarks.

Patients and methods Retrospective analysis of prospectively collected data from all colonoscopies performed between 2015 and 2019 after a positive quantitative FIT in the population-based colorectal cancer screening program conducted in Alsace, part of the French national program. Detection indicators included ADR, mean number of adenomas per colonoscopy, and proximal serrated lesion (SL) detection rate. Characterization indicators included rate of non-neoplastic polyp (NNP) detection.

Results Overall, 13,067 FIT-positive colonoscopies were evaluated, performed by 80 community gastroenterologists. The overall ADR was 57.6 %, and a 10 µg/g increase in fecal hemoglobin concentration was significantly associated with higher ADR (odds ratio [95 % confidence interval] = 1.02 [1.02–1.03]). Endoscopists whose ADR was ≥ 55 % were high detectors for all neoplasia, including proximal SLs and number of adenomas. The rate of detection of NNPs was 39.5 % in highest detectors (ADR > 70 %), significantly higher than in lower detectors (21.4 %) (P < 0.001). There was a strong correlation between detection and characterization indicators, e. g. between rates of detection of proximal SLs and NNPs (Pearson = 0.73; P < 0.01).

Conclusions A single indicator, ADR, is enough to assess endoscopist performance for both detection and characterization in routine practice provided the minimum target standard is raised and a maximum standard is added: 55 % and 70 % for FIT-positive colonoscopies, respectively.



Publication History

Received: 09 November 2021

Accepted after revision: 20 May 2022

Accepted Manuscript online:
23 May 2022

Article published online:
14 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Rex DK, Boland CR, Dominitz JA. et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017; 153: 307-323
  • 2 Denis B, Sauleau EA, Gendre I. et al. Measurement of adenoma detection and characterization during colonoscopy in routine practice: an exploratory study. Gastrointest Endosc 2011; 74: 1325-1336
  • 3 Denis B, Sauleau EA, Gendre I. et al. The mean number of adenomas per procedure should become the gold standard to measure the neoplasia yield of colonoscopy: a population-based cohort study. Dig Liver Dis 2014; 46: 176-181
  • 4 Kaminski MF, Regula J, Kraszewska E. et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362: 1795-1803
  • 5 Baxter NN, Sutradhar R, Forbes SS. et al. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology 2011; 140: 65-72
  • 6 Corley DA, Jensen CD, Marks AR. et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370: 1298-1306
  • 7 Kaminski MF, Wieszczy P, Rupinski M. et al. Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death. Gastroenterology 2017; 153: 98-105
  • 8 Rex DK, Schoenfeld PS, Cohen J. et al. Quality indicators for colonoscopy. Gastrointest Endosc 2015; 81: 31-53
  • 9 Kaminski MF, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49: 378-397
  • 10 Zorzi M, Senore C, Da Re F. et al. Quality of colonoscopy in an organized colorectal cancer screening program with immunochemical fecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy). Gut 2015; 64: 1389-1396
  • 11 Jensen CD, Corley DA, Quinn VP. et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med 2016; 164: 456-463
  • 12 Hilsden RJ, Bridges R, Dube C. et al. Defining benchmarks for adenoma detection rate and adenomas per colonoscopy in patients undergoing colonoscopy due to a positive fecal immunochemical test. Am J Gastroenterol 2016; 111: 1743-1749
  • 13 Cubiella J, Castells A, Andreu M. et al. COLONPREV study investigators. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs. United Europ Gastroenterol J 2017; 5: 255-256
  • 14 Wong JCT, Chiu HM, Kim HS. et al. Adenoma detection rates in colonoscopies for positive fecal immunochemical tests versus direct screening colonoscopies. Gastrointest Endosc 2019; 89: 607-613
  • 15 Robertson DJ, Lee JK, Boland CR. et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017; 152: 1217-1237
  • 16 Crockett SD, Nagtegaal ID. Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia. Gastroenterology 2019; 157: 949-966
  • 17 Mason SE, Poynter L, Takats Z. et al. Optical technologies for endoscopic real-time histologic assessment of colorectal polyps: a meta-analysis. Am J Gastroenterol 2019; 114: 1219-1230
  • 18 Bisschops R, East JE, Hassan C. et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019. Endoscopy 2019; 51: 1155-1179
  • 19 Rees CJ, Rajasekhar PT, Wilson A. et al. Narrow band imaging optical diagnosis of small colorectal polyps in routine clinical practice: the Detect Inspect Characterise Resect and Discard 2 (DISCARD 2) study. Gut 2017; 66: 887-895
  • 20 Denis B, Ruetsch M, Strentz P. et al. Short-term outcomes of the first round of a pilot colorectal cancer screening program with guaiac based fecal occult blood test. Gut 2007; 56: 1579-1584
  • 21 Lee TJ, Rutter MD, Blanks RG. et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut 2012; 61: 1050-1057
  • 22 Corley DA, Jensen CD, Marks AR. et al. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol 2013; 11: 172-180
  • 23 Atia MA, Patel NC, Ratuapli SK. et al. Nonneoplastic polypectomy during screening colonoscopy: the impact on polyp detection rate, adenoma detection rate, and overall cost. Gastrointest Endosc 2015; 82: 370-375
  • 24 Zorzi M, Senore C, Da Re F. et al. Detection rate and predictive factors of sessile serrated polyps in an organized colorectal cancer screening programme with immunochemical fecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy). Gut 2017; 66: 1233-1240
  • 25 Sarvepalli S, Garber A, Rothberg MB. et al. Association of adenoma and proximal sessile serrated polyp detection rates with endoscopist characteristics. JAMA Surg 2019; 154: 627-635
  • 26 Rex DK, Sullivan AW, Perkins AJ. et al. Colorectal polyp prevalence and aspirational detection targets determined using high definition colonoscopy and a high level detector in 2017. Dig Liver Dis 2020; 52: 72-78
  • 27 Bretagne JF, Hamonic S, Piette C. et al. Variations between endoscopists in rates of detection of colorectal neoplasia and their impact on a regional screening program based on colonoscopy after fecal occult blood testing. Gastrointest Endosc 2010; 71: 335-341
  • 28 Wang HS, Pisegna J, Modi R. et al. Adenoma detection rate is necessary but insufficient for distinguishing high versus low endoscopist performance. Gastrointest Endosc 2013; 77: 71-78
  • 29 IJspeert JE, van Doorn SC, van der Brug YM. et al. The proximal serrated polyp detection rate is an easy-to-measure proxy for the detection rate of clinically relevant serrated polyps. Gastrointest Endosc 2015; 82: 870-877
  • 30 Melson J, Berger D, Greenspan M. et al. Maintaining low non-neoplastic polypectomy rates in high-quality screening colonoscopy. Gastrointest Endosc 2017; 85: 581-587
  • 31 Hilsden RJ, Rose SM, Dube C. et al. Defining and applying locally relevant benchmarks for the adenoma detection rate. Am J Gastroenterol 2019; 114: 1315-1321
  • 32 Clark G, Strachan JA, Carey FA. et al. Transition to quantitative fecal immunochemical testing from guaiac fecal occult blood testing in a fully rolled-out population-based national bowel screening programme. Gut 2021; 70: 106-113
  • 33 Anderson JC, Butterly LF, Weiss JE. et al. Providing data for serrated polyp detection rate benchmarks: an analysis of the New Hampshire Colonoscopy Registry. Gastrointest Endosc 2017; 85: 1188-1194
  • 34 Williams JE, Holub JL, Faigel DO. Polypectomy rate is a valid quality measure for colonoscopy: results from a national endoscopy database. Gastrointest Endosc 2012; 75: 576-582
  • 35 Schramm C, Scheller I, Franklin J. et al. Predicting ADR from PDR and individual adenoma-to-polyp-detection-rate ratio for screening and surveillance colonoscopies: A new approach to quality assessment. United European Gastroenterol J 2017; 5: 742-749
  • 36 East JE, Atkin WS, Bateman AC. et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut 2017; 66: 1181-1196
  • 37 Quality assurance guidelines for colonoscopy. NHS Bowel Cancer Screening Program Publication N°6. February 2011. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/427591/nhsbcsp06.pdf
  • 38 Bronzwaer MES, Vleugels JLA, van Doorn SC. et al. Are adenoma and serrated polyp detection rates correlated with endoscopists' sensitivity of optical diagnosis?. Endoscopy 2020; 52: 763-772
  • 39 Chen SC, Rex DK. Variable detection of nonadenomatous polyps by individual endoscopists at colonoscopy and correlation with adenoma detection. J Clin Gastroenterol 2008; 42: 704-707
  • 40 Chen PJ, Lin MC, Lai MJ. et al. Accurate classification of diminutive colorectal polyps using computer-aided analysis. Gastroenterology 2018; 154: 568-575
  • 41 Kaminski MF, Anderson J, Valori R. et al. Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial. Gut 2016; 65: 616-624
  • 42 Denis B, Gendre I, Perrin P. et al. Management of large polyps in a colorectal cancer screening programme with fecal immunochemical test: a community- and population-based observational study. Endosc Int Open 2021; 9: E1649-E1657